Peter Barrett

Synlogic

• 
• 
• 
• 
• 
• http://synlogictx.com/

Overview

Peter Barrett is the current chairman of Synlogic. He is a partner in the life sciences group and focuses on investments in therapeutics and medical technologies that significantly change the medical management of patients. At Atlas, Peter has been involved in the creation of several novel therapeutic and drug discovery platform companies. Peter leverages his background in corporate business development to provide strategic and negotiating guidance to his portfolio; he was instrumental in the sales of Stromedix to Biogen and Novamed to SciClone Pharmaceuticals (NASDAQ: SCLN). He is currently chairman of Harbour Antibodies and Zafgen, and also serves on the boards of Mnemosyne Pharmaceuticals, InfaCare, JenaValve, and Vitae Pharmaceuticals. Peter was previously on the boards of past Atlas companies SciClone Pharmaceuticals, Sirion Therapeutics (acquired by Alcon and Bausch & Lomb), and Archemix (acquired by Baxter).